Hana Biosciences to Present at 3rd Annual PIPES Conference
26 Ottobre 2005 - 2:28PM
Business Wire
Hana Biosciences (AMEX: HBX), a South San Francisco-based
biopharmaceutical company focused on advancing cancer care, will
present at the 3rd Annual PIPES Conference, on Thursday, Oct. 27,
2005, at 9 a.m., 9:30 a.m. and 10 a.m. The presentation will take
place in the Morgan Room at The Waldorf Astoria on 301 Park Avenue,
New York, New York. Fred Vitale, vice president of business
development for Hana Biosciences, will provide an overview of the
market potential of the company's well-rounded oncology pipeline to
an estimated audience of 1,000 investment professionals focused
primarily on small capitalization companies. About Hana Biosciences
Hana Biosciences Inc. is a South San Francisco, Calif.-based
biopharmaceutical company that acquires, develops, and
commercializes innovative products to advance cancer care. The
company is committed to creating value by building a world-class
team, accelerating the development of lead product candidates,
expanding its pipeline by being the alliance partner of choice, and
nurturing a unique company culture. Additional information on Hana
Biosciences can be found at www.hanabiosciences.com. This press
release contains forward-looking statements that involve risks and
uncertainties that could cause Hana's actual results to differ
materially from the anticipated results and expectations expressed
in these forward-looking statements. These statements are based on
current expectations, forecasts and assumptions that are subject to
risks and uncertainties, which could cause actual outcomes and
results to differ materially from these statements. Among other
things, there can be no assurances that any of Hana's development
efforts relating to its product candidates will be successful.
Other risks that may affect forward-looking information contained
in this press release include the possibility of being unable to
obtain regulatory approval of Hana's product candidates, the risk
that the results of clinical trials may not support Hana's claims,
Hana's reliance on third-party researchers to develop its product
candidates and its lack of experience in developing pharmaceutical
products. Additional risks are described in the company's Annual
Report on Form 10-KSB for the year ended Dec. 31, 2004. Hana
assumes no obligation to update these forward-looking statements,
except as required by law.
Grafico Azioni Hana Biosciences (AMEX:HBX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Hana Biosciences (AMEX:HBX)
Storico
Da Set 2023 a Set 2024
Notizie in Tempo Reale relative a Hana Biosciences (Borsa Americana (AMEX)): 0 articoli recenti
Più Hana Biosciences Inc. Articoli Notizie